Author

J. Low

The University of Sydney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Cancer Biology· 3 Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Organism:human· 5 Research Focus:drug response / drug discovery· 4 Research Focus:chromatin & epigenetic regulation· 3 Assay:proteomics· 3 Approach:biophysical modeling· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:protein folding & dynamics· 2

Frequent Co-Authors

B. Young· 3 shared J. Mackay· 3 shared T. Chen· 3 shared A. van Oijen· 2 shared D. Currier· 2 shared D. Lye· 2 shared J. Easton· 2 shared J. Fang· 2 shared

Activity by Year

2019-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

B. Young

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

The BRD4-nucleosome interaction is enhanced modestly and non-selectively by histone acetylation

L. Lambrechts, Xavier J. Reid, Lucas Kambanis, Clement Luong, Erekle Kobakhidze, Andrea Daners, Yichen Zhong, Karishma Patel, Charlotte Franck, Hakimeh Moghaddas Sani, Cameron Taylor, J. Low, Richard J. Payne, Joel P. Mackay

This study investigates BRD4's nucleosomal binding affinity and shows that histone acetylation modestly enhances this interaction, with little dependence on acetylation pattern.

Nucleic Acids Research · Nov 26, 2025Peer-reviewedBiochemistry

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeutics.

H.-M. Lee, W. C. Wright, M. Pan, J. Low, D. Currier, J. Fang, S. Singh, S. Nance, I. Delahunty, Y. Kim, R. H. Chapple, Y. Zhang, X. Liu, J. A. Steele, J. Qi, , P. Geeleher

The paper uses CRISPR knockout screens to identify drug combinations that enhance the effectiveness of common chemotherapeutics in neuroblastoma cells.

bioRxiv · Apr 12, 2023Cancer Biology

The role of auxiliary domains in modulating CHD4 activity suggests mechanistic commonality between enzyme families

Y. Zhong, H. Moghaddas Sani, B. Paudel, J. Low, A. Silva, S. Mueller, C. Deshpande, S. Panjikar, X. Reid, M. Bedward, A. van Oijen, J. Mackay

The paper investigates how auxiliary domains in CHD4 modulate its activity, revealing common regulatory mechanisms across chromatin remodelling enzyme families.

bioRxiv · Jun 13, 2022 · PreprintBiochemistry

Rapid determination of the wide dynamic range of SARS-CoV-2 Spike T cell responses in whole blood of vaccinated and naturally infected

A. T. Tan, J. M. Lim, N. Le Bert, K. Kunasegaran, A. Chia, M. Qui, N. Tan, W. N. Chia, R. Alwis, Y. Ding, E. E. Ooi, L.-F. Wang, M. I. Chen, B. Young, L. Y. Hsu, , A. Bertoletti

This study evaluates a rapid whole blood test for measuring SARS-CoV-2 Spike-specific T cell responses in vaccinated and infected individuals, finding a wide dynamic range independent of neutralizing antibodies.

bioRxiv · Jun 29, 2021 · PreprintImmunology

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

M. Pan, C. Wright, R. Chapple, A. Zubair, M. Sandhu, J. Batchelder, J. Low, K. Blankenship, L. Wang, B. Gordon, P. Archer, S. W. Brady, S. Natarajan, M. Pozsgai, J. Schuetz, , P. Geeleher

This study identifies CX-5461 as a TOP2B inhibitor with selective activity in high-risk neuroblastoma but highlights safety concerns due to TOP2B off-target effects.

bioRxiv · Feb 25, 2021Cancer Biology

A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilizing immunity against SARS-CoV-2 infection in mice

C. Counoupas, M. D. Johnson, A. Stella, D. H. Nguyen, A. Ferguson, A. Aggarwal, N. Bhattacharyya, A. Grey, K. Patel, R. Siddiquee, E. L. Stewart, O. Hutchings, C. Feng, N. G. G. Hansbro, U. Palendira, , J. A. Triccas

A BCG-adjuvanted vaccine provides sterilizing immunity against SARS-CoV-2 in mice, with high neutralizing antibody titers and Th1 responses.

bioRxiv · Dec 10, 2020 · PreprintMicrobiology

Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2

Y. Su, D. Anderson, B. Young, F. Zhu, M. Linster, S. Kalimuddin, J. Low, Z. Yan, J. Jayakumar, L. Sun, G. Yan, I. Mendenhall, Y.-S. Leo, D. Lye, L.-F. Wang, G. Smith

The paper identifies a 382-nt deletion in SARS-CoV-2 ORF8 from Singapore patients, which enhances N gene transcription and may contribute to viral attenuation.

bioRxiv · Mar 11, 2020 · PreprintMicrobiology

Geldanamycin inhibits Jumonji histone lysine demethylase KDM4 and targets chimeric transcription factor PAX3-FOXO1

A. Abu-Zaid, S. Singh, W. LIN, J. Low, A. Abdolvahabi, B. Bailey Cooke, J. Bowling, S. Vaithiyalingam, J. Fang, D. Currier, M.-K. Yun, A. AlTahan, D. Fernando, J. Maier, H. Tillman, , J. YANG

This study identifies geldanamycin and its analog 17-DMAG as dual KDM/Hsp90 inhibitors effective against PAX3-FOXO1-driven rhabdomyosarcoma.

bioRxiv · Dec 11, 2019 · PreprintCancer Biology

CHD4 slides nucleosomes by decoupling entry- and exit-side DNA translocation

Y. Zhong, B. P. Paudel, D. Ryan, J. Low, C. Franck, K. Patel, M. Benward, R. Payne, A. van Oijen, J. Mackay

This study investigates the mechanism of CHD4-mediated nucleosome sliding using single-molecule assays, revealing a decoupling of DNA translocation at entry and exit sides.

bioRxiv · Jun 27, 2019Biochemistry